Adjuvant Therapy for Non-Small Cell Lung Cancer: Impact of Recent Clinical Trials on Community Practice
Non-small cell lung cancer (NSCLC) is diagnosed at an early stage, when it is amenable to surgical resection in approximately 20% to 25% of cases.